Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome

Journal of Endocrinological Investigation

Volumn 27, Issue 10, 2004, Pages 969-974

  Putignano, P ^a   Pecori Giraldi, F ^a   Cavagnini, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

11 hydroxysteroid dehydrogenase type 1; Cortisol; Cortisone; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; LIPID; PROTEIN;

ACCURACY; ADIPOSE TISSUE; CASE CONTROL STUDY; CLINICAL FEATURE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG RESEARCH; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; GLUCOSE METABOLISM; HORMONAL REGULATION; HUMAN; HYDROCORTISONE RELEASE; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER PARENCHYMA; MEDICAL ASSESSMENT; METABOLIC SYNDROME X; MUSCLE TISSUE; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PROTEIN METABOLISM; SHORT SURVEY; SKELETAL MUSCLE; TISSUE SPECIFICITY; UPREGULATION;

EID: 12344320552     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347544     Document Type: Short Survey

References (48)

1. Phillips DIW, Barker DJP, Fall CHD, et al. Elevated plasma cortisol concentrations: an explanation for the relationship between low birthweight and adult cardiovascular risk factors. J Clin Endocrinol Metab 1998, 83: 757-60.
2. Walker BR. Steroid metabolism in metabolic syndrome X. Best Pract Res Clin Endocrinol Metab 2001, 15: 111-22.
3. Putignano P, Bertolini M, Losa M, Cavagnini F. Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome. J Endocrinol Invest 2003, 26: 539-44.
4. Huizenga NA, de Lange P, Koper JW, et al. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998, 83: 144-51.
5. Rosmond R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obes Res 2002, 10: 1078-86.
6. Van Rossum EF, Koper JW, Huizenga NA, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002, 51: 3128-34.
7. Walker BR, Phillips DIW, Noon JP, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998, 31: 891-5.
8. Seckl JR, Walker BR. 11β-Hydroxysteroid dehydrogenase type 1-a tissue specific amplifier of glucocorticoid action. Endocrinology 2001, 142: 1371-6.
9. Davani B, Khan A, Hult M, et al. Type 1 11beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J Biol Chem 2000, 275: 34841-4.
10. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, Walker BR. Local and systemic impact of transcriptional upregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 2003, 88: 3988-9.
11. Hermanowski-Vosatka A, Gerhold D, Mundt SS, et al. PPA-Ralpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver. Biochem Biophys Res Commun 2000, 279: 330-6.
12. Berger J, Tanen M, Elbrecht A, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001, 276: 12629-35.
13. Stulnig TM, Opperman U, Steffensen KR, Schuster GU, Gustafsson JA. Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 2002, 51: 2426-33.
14. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adiopose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology 1999, 140: 3188-96.
15. Tomlinson JW, Moore J, Cooper MS, et al. Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 2001, 142: 1982-9.
16. Brunner EJ, Hemingway H, Walker BR, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002, 106: 2634-6.
17. Reynolds RM, Walker BR. Human insulin resistance: the role of glucocorticoids. Diabetes Obes Metab 2003, 5: 5-12.
18. Dimitriadis G, Leighton B, Parry-Billings M, et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 1997, 321: 707-12.
19. Brindley DN. Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Int J Obes 1995, 19: S69-S75.
20. Kelly JJ, Mangos G. Williamson PM, Whitworth JA. Cortisol and hypertension. Clin Exp Pharmacol Physiol Suppl 1998, 25: S51-S56.
21. Litchfield WR, Hunt SC, Jeunemaitre X, et al. Increased urinary free cortisol. A potential intermediate phenotype of essential hypertension. Hypertension 1998, 31: 569-74.
22. Reynolds RM, Walker BR, Sydall HE, et al. Altered control of cortisol secretion in adult men with low birthweight and cardiovascular risk factors. J Clin Endocrinol Metab 2001, 86: 245-50.
23. Putignano P, Kaltsas GA, Korbonits M, et al. Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment. J Clin Endocrinol Metab 2000, 85: 3309-12.
24. Koh JM, Kim JY, Chung YE, et al. Increased urinary albumin excretion in Cushing's syndrome: remission after correction of hypercortisolaemia. Clin Endocrinol (Oxf) 2000, 5: 349-53.
25. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998, 83: 1853-9.
26. Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the activities of 11β-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. J Clin Endocrinol Metab 2002, 87: 277-85.
27. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and metabolic syndrome. Science 2001, 294: 2166-170.
28. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003, 112: 83-90.
29. Morton NM, Holmes MC, Fievet C. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001, 276: 41293-300.
30. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997, 94: 14924-9.
31. Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45: 1528-32.
32. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone to cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999, 84: 1022-7.
33. Homma M, Tanaka A, Hino K, et al. Assessing systemic 11β-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure. Metabolism 2001, 50: 801-4.
34. Andrews RC, Herlihy O, Livingstone DEW, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 2002, 87: 5587-93.
35. Kerstens MN, Riemens SC, Sluiter WJ, Pratt JJ, Wolthers BG, Dullaart RBF. No relation between 11β-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24 hour of insulin infusion in healthy subjects and type 2 diabetic subjects. Clin Endocrinol (Oxf) 2000, 52: 403-11.
36. Andrew R, Gale CR, Walker BR, Seckl JR, Martyn CN. Glucocorticoid metabolism and the metabolic syndrome: associations in an elderly cohort. Exp Clin Endocrinol Diabetes 2002, 110: 284-90.
37. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome: evidence of dysregulation of 11beta-hydroxysteroid dehydrogenase. N Engl J Med 1994, 330: 460-5.
38. Draper N, Echwald SM, Lavery GG, et al. Association studies between microsatellite markers within the gene encoding human 11β-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J Clin Endocrinol Metab 2002, 87: 4984-90.
39. Tomlinson JW, Draper N, Mackie J, et al. Absence of cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002, 87: 57-62.
40. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001, 86: 1418-21.
41. Livingstone DEW, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000, 141: 560-3.
42. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women; increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002, 87: 3330-6.
43. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002, 87: 2701-5.
44. Whorwood CB, Donovan SJ, Wood PJ, Phillips DIW. Regulation of glucocorticoid receptor α and β isoforms and type I 11β -hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J Clin Endocrinol Metab 2001, 86: 2296-308.
45. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI., Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002, 51: 1066-75.
46. Andrews RC, Rooyackers O, Walker BR. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003, 88: 285-91.
47. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC. Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 2001, 142: 114-20.
48. Hanafusa J, Mune T, Tanahashi T, et al. Altered corticosteroid metabolism differentially affects pituitary corticotropin response. Am J Physiol Endocrinol Metab 2002, 282: E466-E473.